Mast cells activate the renin angiotensin system and contribute to migraine: A hypothesis

Headache

Volumn 48, Issue 10, 2008, Pages 1499-1505

  Ba'albaki, Hisham ^a,b   Rapoport, Alan ^c,d  

^a Heart Health Center PC   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW ENGLAND CENTER FOR HEADACHE   (United States)

Author keywords

Angiotensin blockade; Angiotensin converting enyme; Angiotensin receptor blocker; Chymase; Headache prevention; Mast cell; Migraine; Neurogenic inflammation

Indexed keywords

ALISKIREN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERGOTAMINE; HYDRALAZINE; LISINOPRIL; RENIN; RENIN INHIBITOR; TRIPTAN DERIVATIVE; VASODILATOR AGENT;

BRAIN; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; DEGRANULATION; HEART; HUMAN; INFLAMMATION; MAMMAL; MAST CELL; MAST CELL DEGRANULATION; MENINGITIS; MIGRAINE; MONOTHERAPY; MORBIDITY; NERVE ENDING; NEUROGENIC INFLAMMATION; NOCICEPTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TRIGEMINAL NERVE; VASODILATATION;

ANIMALS; CEREBRAL ARTERIES; CEREBROVASCULAR CIRCULATION; HUMANS; INFLAMMATION; MAST CELLS; MENINGES; MIGRAINE DISORDERS; NOCICEPTORS; RENIN-ANGIOTENSIN SYSTEM; VASOCONSTRICTION;

EID: 56549125179     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2008.00852.x     Document Type: Review

References (47)

1. Nickenig G, Harrison DG. The AT(1)-type angiotensin receptor in oxidative stress and atherogenesis: Part I: Oxidative stress and atherogenesis. Circulation. 2002 105 : 393 396.
2. Tham DM, Martin-McNulty B, Wang YX, et al. Angiotensin II is associated with activation of NF-kappaB-mediated genes and downregulation of PPARs. Physiol Genomics. 2002 11 : 21 30.
3. Mackins CJ, Kano S, Seyedi N, et al. Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. J Clin Invest. 2006 116 : 1063 1070.
4. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 1995 95 : 995 1001.
5. Sicuteri F. Enkephalinase inhibition relieves pain syndromes of central dysnociception (migraine and related headache). Cephalalgia. 1981 1 : 229 232.
6. Schrader H, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): Randomised, placebo controlled, crossover study. BMJ. 2001 322 : 19 22.
7. Tronvik E, Stovner LJ, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: A randomized controlled trial. JAMA. 2003 289 : 65 69.
8. Rahimtoola H, Buurma H, Tijssen CC, Leufkens HG, Egberts AC. Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy - a pilot study. Pharmacoepidemiol Drug Saf 2004 13 : 41 47.
9. Tronvik E, Stovner LJ, Schrader H, Bovim G. Involvement of the renin-angiotensin system in migraine. J Hypertens Suppl. 2006 24 : S139 143.
10. Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J Neuroimmunol. 2004 146 : 1 12.
11. Dalessio DJ. The relationship of vasoactive substances to vascular permeability, and their role in migraine. Res Clin Stud Headache. 1976 4 : 76 84.
12. Theoharides TC, Donelan J, Kandere-Grzybowska K, Konstantinidou A. The role of mast cells in migraine pathophysiology. Brain Res Brain Res Rev. 2005 49 : 65 76.
13. Levy D, Burstein R, Strassman AM. Mast cell involvement in the pathophysiology of migraine headache: A hypothesis. Headache. 2006 46 (suppl 1 S13 18.
14. Reuter U, Bolay H, Jansen-Olesen I, et al. Delayed inflammation in rat meninges: Implications for migraine pathophysiology. Brain. 2001 124 : 2490 2502.
15. Manna SK, Ramesh GT. Interleukin-8 induces nuclear transcription factor-kappaB through a TRAF6dependent pathway. J Biol Chem. 2005 280 : 7010 7021.
16. Sarchielli P, Floridi A, Mancini ML, et al. NF-kappaB activity and iNOS expression in monocytes from internal jugular blood of migraine without aura patients during attacks. Cephalalgia. 2006 26 : 1071 1079.
17. von Bohlen und Halbach O. The renin-angiotensin system in the mammalian central nervous system. Curr Protein Pept Sci. 2005 6 : 355 371.
18. Davisson RL, Oliverio MI, Coffman TM, Sigmund CD. Divergent functions of angiotensin II receptor isoforms in the brain. J Clin Invest. 2000 106 : 103 106.
19. Pelegrini-da-Silva A, Martins AR, Prado WA. A new role for the renin-angiotensin system in the rat periaqueductal gray matter: Angiotensin receptor-mediated modulation of nociception. Neuroscience. 2005 132 : 453 463.
20. Carvalho RF, Ribeiro RA, Falcao RA, et al. Angiotensin II potentiates inflammatory edema in rats: Role of mast cell degranulation. Eur J Pharmacol. 2006 540 : 175 182.
21. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res. 1999 84 : 695 703.
22. Wolf G, Wenzel U, Burns KD, Harris RC, Stahl RA, Thaiss F. Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors. Kidney Int. 2002 61 : 1986 1995.
23. Hernandez-Presa M, Bustos C, Ortego M, et al. Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 1997 95 : 1532 1541.
24. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension. 1992 19 : 753 757.
25. Dreier JP, Kleeberg J, Petzold G, et al. Endothelin-1 potently induces Leao's cortical spreading depression in vivo in the rat: A model for an endothelial trigger of migrainous aura? Brain. 2002 125 : 102 112.
26. Zimmerman MC, Lazartigues E, Sharma RV, Davis-son RL. Hypertension caused by angiotensin II infusion involves increased superoxide production in the central nervous system. Circ Res. 2004 95 : 210 216.
27. Ciancarelli I, Tozzi-Ciancarelli MG, Di Massimo C, Marini C, Carolei A. Flunarizine effects on oxidative stress in migraine patients. Cephalalgia. 2004 24 : 528 532.
28. Kowa H, Fusayasu E, Ijiri T, et al. Association of the insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients of migraine with aura. Neurosci Lett. 2005 374 : 129 131.
29. Paterna S, Di Pasquale P, D'Angelo A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol. 2000 43 : 133 136.
30. Nabel EG. Cardiovascular disease. N Engl J Med. 2003 349 : 60 72.
31. Yu H, Zhang Y, Liu G. Relationship between polymorphism of the angiotensin-converting enzyme gene and the response to angiotensin-converting enzyme inhibition in hypertensive patients. Hypertens Res. 2003 26 : 881 886.
32. Le TH, Coffman TM. A new cardiac MASTer switch for the renin-angiotensin system. J Clin Invest. 2006 116 : 866 869.
33. Jenne DE, Tschopp J. Angiotensin II-forming heart chymase is a mast-cell-specific enzyme. Biochem J. 1991 276 : 567 568.
34. Urata H, Boehm KD, Philip A, et al. Cellular localization and regional distribution of an angiotensin II-forming chymase in the heart. J Clin Invest. 1993 91 : 1269 1281.
35. Li P, Chen PM, Wang SW, Chen LY. Time-dependent expression of chymase and angiotensin converting enzyme in the hamster heart under pressure overload. Hypertens Res. 2002 25 : 757 762.
36. Kokkonen JO, Lindstedt KA, Kovanen PT. Role for chymase in heart failure: Angiotensin II-dependent or -independent mechanisms? Circulation. 2003 107 : 2522 2524.
37. Kurth T, Gaziano JM, Cook NR, Logroscino G, Diener HC, Buring JE. Migraine and risk of cardiovascular disease in women. JAMA. 2006 296 : 283 291.
38. Sternfeld B, Stang P, Sidney S. Relationship of migraine headaches to experience of chest pain and subsequent risk for myocardial infarction. Neurology. 1995 45 : 2135 2142.
39. Pang X, Alexacos N, Letourneau R, et al. A neurotensin receptor antagonist inhibits acute immobilization stress-induced cardiac mast cell degranulation, a corticotropin-releasing hormone-dependent process. J Pharmacol Exp Ther. 1998 287 : 307 314.
40. Theoharides TC, Spanos C, Pang X, et al. Stress-induced intracranial mast cell degranulation: A corticotropin-releasing hormone-mediated effect. Endocrinology. 1995 136 : 5745 5570.
41. Eikermann A, Diener HC. Effect of active treatment is lower when using placebo control in clinical trials on acute therapy of migraine. Cephalalgia. 2003 23 : 344 347.
42. Miller JA, Cherney DZ, Duncan JA, et al. Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol. 2006 17 : 2554 2560.
43. Kawasaki H, Inaizumi K, Nakamura A, Hobara N, Kurosaki Y. Chronic angiotensin II inhibition increases levels of calcitonin gene-related peptide mRNA of the dorsal root ganglia in spontaneously hypertensive rats. Hypertens Res. 2003 26 : 257 263.
44. Arulmani U, Maassenvandenbrink A, Villalon CM, Saxena PR. Calcitonin gene-related peptide and its role in migraine pathophysiology. Eur J Pharmacol. 2004 500 : 315 330.
45. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med. 2004 350 : 1104 1110.
46. Ho T, Mannix L, Fan X, Assaid C, Furtek C, Jones C, Rapoport A. Efficacy and tolerability of a novel, oral CGRP antagonist, MK-0974, in the acute treatment of migraine: Results from a phase 2 randomized, controlled, clinical trial. Headache. 2007 47 : 748 (abstract).
47. Azizi M, Webb R, Nussberger J, Hollenberg NK. Renin inhibition with aliskiren: Where are we now, and where are we going? J Hypertens. 2006 24 : 243 256.